Scinai Immunotherapeutics (SCNI) Competitors $1.50 -0.06 (-3.85%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.56 +0.06 (+4.27%) As of 09/5/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SCNI vs. PALI, TTNP, PBM, GNPX, PPBT, APVO, AKAN, KTTA, LIAN, and ADTXShould you be buying Scinai Immunotherapeutics stock or one of its competitors? The main competitors of Scinai Immunotherapeutics include Palisade Bio (PALI), Titan Pharmaceuticals (TTNP), Psyence Biomedical (PBM), Genprex (GNPX), Purple Biotech (PPBT), Aptevo Therapeutics (APVO), Akanda (AKAN), Pasithea Therapeutics (KTTA), LianBio (LIAN), and Aditxt (ADTX). These companies are all part of the "pharmaceutical products" industry. Scinai Immunotherapeutics vs. Its Competitors Palisade Bio Titan Pharmaceuticals Psyence Biomedical Genprex Purple Biotech Aptevo Therapeutics Akanda Pasithea Therapeutics LianBio Aditxt Palisade Bio (NASDAQ:PALI) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk. Which has preferable valuation & earnings, PALI or SCNI? Scinai Immunotherapeutics has higher revenue and earnings than Palisade Bio. Scinai Immunotherapeutics is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPalisade Bio$250K22.85-$14.44M-$4.06-0.15Scinai Immunotherapeutics$660K2.27$4.80M-$9.57-0.16 Do analysts rate PALI or SCNI? Palisade Bio presently has a consensus target price of $12.00, suggesting a potential upside of 1,815.40%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts plainly believe Palisade Bio is more favorable than Scinai Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palisade Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Scinai Immunotherapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is PALI or SCNI more profitable? Scinai Immunotherapeutics' return on equity of 0.00% beat Palisade Bio's return on equity.Company Net Margins Return on Equity Return on Assets Palisade BioN/A -214.94% -135.09% Scinai Immunotherapeutics N/A N/A -40.60% Do institutionals & insiders have more ownership in PALI or SCNI? 11.8% of Palisade Bio shares are owned by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 0.7% of Palisade Bio shares are owned by company insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer PALI or SCNI? In the previous week, Palisade Bio had 5 more articles in the media than Scinai Immunotherapeutics. MarketBeat recorded 6 mentions for Palisade Bio and 1 mentions for Scinai Immunotherapeutics. Palisade Bio's average media sentiment score of 0.33 beat Scinai Immunotherapeutics' score of 0.00 indicating that Palisade Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scinai Immunotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, PALI or SCNI? Palisade Bio has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. SummaryPalisade Bio beats Scinai Immunotherapeutics on 8 of the 15 factors compared between the two stocks. Get Scinai Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SCNI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCNI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCNI vs. The Competition Export to ExcelMetricScinai ImmunotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.50M$3.17B$5.83B$9.92BDividend YieldN/A2.26%6.70%4.52%P/E Ratio-0.1621.1076.1526.11Price / Sales2.27471.55563.98189.73Price / CashN/A45.7236.9959.28Price / Book0.299.8711.486.09Net Income$4.80M-$53.42M$3.29B$266.51M7 Day Performance-1.96%2.93%1.27%0.45%1 Month Performance-2.60%11.43%8.56%5.05%1 Year Performance-58.31%16.14%61.18%26.03% Scinai Immunotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCNIScinai Immunotherapeutics0.7249 of 5 stars$1.50-3.8%N/A-58.3%$1.50M$660K-0.1620PALIPalisade Bio2.7989 of 5 stars$0.67-1.1%$12.00+1,688.4%-82.5%$6.12M$250K-0.1710News CoverageTTNPTitan Pharmaceuticals0.738 of 5 stars$4.47-10.7%N/A-26.2%$5.94MN/A-1.5110Positive NewsShort Interest ↓High Trading VolumePBMPsyence Biomedical0.4957 of 5 stars$3.18-0.5%N/A-97.6%$5.94MN/A0.00N/ANews CoveragePositive NewsShort Interest ↑GNPXGenprex0.9868 of 5 stars$0.18+3.8%N/A-51.2%$5.89MN/A0.0020Short Interest ↑PPBTPurple Biotech2.7708 of 5 stars$2.25+1.6%$33.00+1,369.9%N/A$5.82MN/A-5.3520News CoveragePositive NewsShort Interest ↓APVOAptevo Therapeutics2.9384 of 5 stars$1.77-4.6%$219,040.00+12,410,098.3%-100.0%$5.81M$3.11M0.0050News CoverageShort Interest ↓AKANAkanda0.5877 of 5 stars$3.97-8.9%N/A-49.8%$5.67M$836.66K0.00110Short Interest ↑Gap DownHigh Trading VolumeKTTAPasithea Therapeutics1.2301 of 5 stars$0.74+5.4%N/A-81.1%$5.52MN/A-0.103Short Interest ↓LIANLianBioN/A$0.05+0.4%N/A-84.3%$5.51MN/A-0.06110Gap UpADTXAditxtN/A$1.09+2.4%N/A-100.0%$5.40M$130K0.0060 Related Companies and Tools Related Companies Palisade Bio Alternatives Titan Pharmaceuticals Alternatives Psyence Biomedical Alternatives Genprex Alternatives Purple Biotech Alternatives Aptevo Therapeutics Alternatives Akanda Alternatives Pasithea Therapeutics Alternatives LianBio Alternatives Aditxt Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCNI) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scinai Immunotherapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Scinai Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
